您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Triptorelin(trifluoroacetate salt)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Triptorelin(trifluoroacetate salt)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Triptorelin(trifluoroacetate salt)图片
CAS NO:2240176-35-4
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
A synthetic GNRH peptide agonist
Cas No.2240176-35-4
Canonical SMILESO=C([C@@H]1CCC(N1)=O)N[C@@H](CC2=CN=CN2)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CO)C(N[C@@H](CC5=CC=C(O)C=C5)C(N[C@H](CC6=CNC7=CC=CC=C67)C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N8CCC[C@H]8C(NCC(N)=O)=O)=O=C([C@@H]1CCC(N1)=O)N[C@@H](CC2=CN=CN2)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CO)C(N[C@@H](CC5=CC=C(O)C=C5)C(N[C@H](CC6=CNC7=CC=CC=C67)C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N8CCC[C@H]8C(NCC(N)=O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
分子式C64H82N18O13• XCF3COOH
分子量1311.4
溶解度DMF: 10mg/mL,DMSO: 3mg/mL,PBS (pH 7.2): 3mg/mL
储存条件-20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) peptide agonist that binds to the GnRH receptor (GnRHR; Ki= 0.3 nM in CHO cells expressing the human receptor).1It inhibits the growth of DU145, LNCaP, and PC3 prostate and OVCAR-3 ovarian cancer cells (IC50s = 62.1, 73.4, 98.1, and 67.7 μM, respectively).2Triptorelin also inhibits the growth of the triple-negative breast cancer (TNBC) cell lines HCC1806 and MDA-MB-231 (EC50s = 58.29 and 31.59 μM, respectively).3It stimulates follicle stimulating hormone (FSH) and luteinizing hormone (LH) release from primary rat pituitary cells when used at a concentration of 50 nM.2It also decreases tumor volume of Dunning R3327H prostate tumor flank implants and reduces prostate and testis weight in rats when administered at a dose of 1 mg/kg per day.4Formulations containing triptorelin have been used in the palliative treatment of advanced prostate cancer.

1.Nederpelt, I., Georgi, V., Schiele, F., et al.Characterization of 12 GnRH peptide agonists - a kinetic perspectiveBr. J. Pharmacol.173(1)128-141(2016) 2.Varamini, P., Rafiee, A., Giddam, A.K., et al.Development of new gonadotropin-releasing hormone-modified dendrimer platforms with direct antiproliferative and gonadotropin releasing activityJ. Med. Chem.60(20)8309-8320(2017) 3.Kwok, C.W., Treeck, O., Buchholz, S., et al.Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)Target Oncol.10(3)365-373(2015) 4.Princivalle, M., Broqua, P., White, R., et al.Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonistJ. Pharmacol. Exp. Ther.320(3)1113-1118(2007)